MBX Biosciences
MBX
54.54
-2.38
-4.18%
MBX Biosciences
US · MBX
#2567 by market cap
Listed 2024
54.54
-2.38
-4.18%
Live - 5344 symbols - heartbeat 15s ago
· 2026-10-07 23:20
After-hours
54.32
-0.40%
Overnight
55.19
+1.19%
- Market cap
- 2.63B
- P/E (TTM)i
- -23.01
- P/Bi
- 6.41
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on MBX?
Anonymous reader poll. Unscientific, not investment advice.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
- Founded
- 2018
- CEO
- Mr. Stephen L. Hoerter
- Employees
- 63
- Headquarters
- Carmel, Indiana, United States of America
- Fiscal year end
- 12-31
- Website
- mbxbio.com
Company profile
- Exchange
- US
- Symbol
- MBX
- Market-cap rank
- #2567
- Listing date
- 2024-09-13
- Market cap
- 2.63B
- Float cap
- 1.69B
- Shares out
- 48.16M
- Float shares
- 30.99M
Sectors & themes
Quote time 2026-10-07 23:20:28 · For reference only, not investment advice and not tailored to your situation.